NS Pharma
BiotechJapan
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
16
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 31
Phase 23
By Therapeutic Area
top 2
Rare Disease
240%
Immunology
120%
R&D Momentum
44/100
Pipeline Velocity
11/100
Trial Completion Rate
83/100
Pipeline Concentration
36/100
Pipeline Freshness
73/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 20, 2026
Approved for marketing
The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation
Sep 16, 2026
Active, not recruiting
A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)
Earlier
Jul 1, 2026TrialA Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Jul 1, 2026TrialClinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Mar 15, 2026TrialRACER53: Viltolarsen in Duchenne Muscular Dystrophy
Sep 18, 2024TrialNS-050/NCNP-03 in Boys With DMD (Meteor50)
Dec 20, 2023TrialTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Jan 31, 2023TrialStudy to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
4 more events
Jul 1, 2021TrialStudy to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
Jun 10, 2021TrialLong-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
Apr 13, 2021TrialStudy to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Jul 6, 2017TrialExtension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Unknown / Other
Immunology
Rare Disease
Duchenne Muscular Dystrophy
ViltepsoPhase 3
NS-089/NCNP-02Phase 2
Unknown / Other
DMD
NS-050/NCNP-03Phase 2
NS-089/NCNP-02Phase 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)